<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

A Closer Look at the Most Recent NCCN Guidelines for Bladder Cancer

Default sub title

minute read

Written by Targeted Oncology on January 24, 2023

The treatment landscape for patients with bladder cancer has rapidly changed with the addition of PD-1 and PD-L1 inhibitors approved for urothelial carcinoma, antibody drug conjugates like enfortumab vedotin-ejfv (Pacdev), and also targeted agents such as erdafitinib (Balversa) for patients with select FGFR mutations.

Topics: Press Coverage

Related Stories